A professional integrated clinical CRO service provider — Shanghai UnionClin Pharmaceutical Technology Co., Ltd. (UnionClin) — announces its participation in BIO Asia-Taiwan 2026.

Scheduled to take place from July 16 to 19, 2026, on the 4th Floor of Taipei Nangang Exhibition Center Hall 1, the event is expected to attract over 50,000 professional visitors and 600 exhibiting enterprises.

As a dedicated practitioner of integrated clinical CRO services focusing on oncology, autoimmune diseases and neurological disorders, UnionClin upholds its mission:Accelerate clinical development for new drugs, and forge new hope for patients worldwide.

At the exhibition, UnionClin will fully showcase its comprehensive service portfolio covering clinical operation, medical affairs, data management & biostatistics, regulatory services, independent IRC imaging assessment, bioanalysis, pharmacovigilance (PV) and SMO services.

I. Deep Expertise in Core Therapeutic Areas with Over 400 Completed Projects

Since its establishment in 2017, UnionClin has undertaken more than 400 clinical projects, built in-depth partnerships with over 2,000 clinical investigators and 1,000+ research sites. With a professional team of over 500 employees, its business footprint covers more than 100 cities across China.

• OncologyUnionClin boasts experience in 90+ segmented indication projects, covering over 30 drug modalities including ADCs, CAR-T, PROTACs, oncolytic viruses and tumor vaccines. Half of the projects are early-phase clinical trials, and the other half are Phase II/III studies.

• Autoimmune DiseasesThe company has accumulated 100+ non-oncology projects covering indications such as IBD, SLE/LN, psoriasis, gout and hyperuricemia, and built abundant high-quality PI resources in the field.

• Neurological DisordersThe company conducts clinical trials for neurological diseases including stroke, Parkinson’s disease, migraine, acute and chronic pain, Alzheimer’s disease, autism and more. It maintains close collaboration with leading clinical experts and research institutions, with nearly 30 successfully delivered clinical research projects for neurological drugs.

II. Academic Ecosystem Development to Boost Brand Influence

UnionClin continues to build a robust academic ecosystem by hosting high-end academic events nationwide, including Innovation Drug Clinical Trial Summits, Oncology New Drug Academic Salons, Fuzhongyou Clinical Salon, and autoimmune disease academic seminars.

The events gather top PIs and new drug R&D elites to share cutting-edge insights, discuss challenges in trial design and translational medicine, and explore optimal pathways for clinical development.

The company’s exclusive PI interview program Clinical Insights invites frontline clinical researchers and imaging experts to discuss challenges and opportunities in new drug R&D from practical clinical perspectives, with each episode exceeding 40,000 views.

During 2024–2025, UnionClin was listed in Arterial Network Top 100 Future Healthcare Enterprises 2025, awarded Best Customer Satisfaction Pharmaceutical CRO, recognized by the Shanghai Science and Technology Commission as a CRO with international service capabilities, and selected for the 2025 Annual Excellent Innovation Case Award for Innovative Drugs & Supply Chain.

Event Information

Event Name: BIO Asia-Taiwan 2026Date: July 16 (Thu) – July 19 (Sun), 2026Venue: 4th Floor, Taipei Nangang Exhibition Center Hall 1, No.1 Jingmao 2nd Road, Nangang District, Taipei

About UnionClin

Founded in 2017, Shanghai UnionClin Pharmaceutical Technology Co., Ltd. (UnionClin) is headquartered in Zhangjiang, Shanghai, with branch offices in Guangzhou, Nanjing, Wuhan and Beijing.

Committed to becoming the preferred clinical partner in oncology, autoimmune diseases and neurological disorders, UnionClin delivers one-stop integrated solutions for new drug clinical trials.

Official Website: www.unionclin.comBusiness Inquiry: bd@unionclin.comTel: +86-21-5830 1389

We welcome you to visit UnionClin at BIO Asia-Taiwan 2026 for face-to-face exchanges, and explore together the pathways to accelerating new drug clinical development.